Busch Matthew C. 4

What Happened

• Matthew C. Busch, Vice President, Finance & Chief Accounting Officer of Amgen, received equity awards on 2026-05-05: a derivative award of 2,969 units (grant value reported at $329.59 each, total ~$978,553) and an additional 455 shares recorded at $0.00 (see footnotes). On 2026-05-06, 50 shares were disposed/withheld at $329.59 per share to cover tax liability (total $16,480). These awards are compensation grants, not open-market purchases or sales.

Key Details

• Transaction dates/prices:
  • 2026-05-05: Award/acquisition — 2,969 derivative units @ $329.59 (total $978,553)
  • 2026-05-05: Award/acquisition — 455 shares @ $0.00 (includes dividend equivalents)
  • 2026-05-06: Tax withholding/payment — 50 shares @ $329.59 (disposed) = $16,480
• Shares owned after the transaction: not stated in the filing.
• Footnotes from the filing:
  • F1: The RSUs vest in four equal annual installments (25% per year), commencing 5/5/2027; vested RSUs are paid one-for-one in common stock.
  • F2: The 455 shares include 45 Dividend Equivalents credited to unvested RSUs and paid out according to the vesting schedule (with cash for any fractional shares).
  • F3: The 2,969 derivative units correspond to non‑qualified stock options that vest/exercise in four equal annual installments beginning 5/5/2027.
• Filing timeliness: Report filed 2026-05-07 for transactions on 2026-05-05–05-06 (appears timely).

Context

• These entries are company compensation awards (RSUs and stock options) and a routine tax-withholding disposition — not an open-market sale indicating a change in conviction.
• The derivative grant (options) is subject to multi-year vesting and is not immediately exercisable or sold; RSU and dividend-equivalent shares vest over time per the schedule in the footnotes.